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A Novel Role For Nanog As An Early 
Cancer Risk Marker In Patients With 
Laryngeal Precancerous Lesions
Juan P. Rodrigo1, M. Ángeles Villaronga1, Sofía T. Menéndez1, Francisco Hermida-Prado1, 
Miquel Quer2, Isabel Vilaseca3, Eva Allonca1, Daniel Pedregal Mallo1, Aurora Astudillo4 & 
Juana M. García-Pedrero1
NANOG is a master regulator of embryonic stem cell pluripotency, found to be frequently aberrantly 
expressed in a variety of cancers, including laryngeal carcinomas. This study investigates for the 
first time the role of NANOG expression in early stages of laryngeal tumourigenesis and its potential 
utility as cancer risk marker. NANOG protein expression was evaluated by immunohistochemistry 
using two large independent cohorts of patients with laryngeal precancerous lesions, and correlated 
with clinicopathological parameters and laryngeal cancer risk. NANOG expression was detected by 
immunohistochemistry in 49 (60%) of 82 laryngeal dysplasias, whereas expression was negligible in 
patient-matched normal epithelia. Strong NANOG expression was found in 22 (27%) lesions and was 
established as cut-off point, showing the most robust association with laryngeal cancer risk (P = 0.003) 
superior to the histological classification (P = 0.320) the current gold standard in the clinical practice. 
Similar trends were obtained using a multicenter validation cohort of 86 patients with laryngeal 
dysplasia. Our findings uncover a novel role for NANOG expression in laryngeal tumourigenesis, and its 
unprecedented application as biomarker for cancer risk assessment.
NANOG is a key transcription factor critical for the acquisition and maintenance of both embryonic and induced 
pluripotency1, 2. In addition to its critical role during embryogenesis3, 4, it has been recently demonstrated that 
NANOG exerts a lineage-restricted mitogenic function in stratified epithelia in adult tissues5. Inducible ubiqui-
tous overexpression of NANOG in mice selectively caused hyperplasia in stratified epithelia, as well as increased 
proliferation and aneuploidy. In addition, NANOG overexpression in mouse skin epithelia was found to favour 
malignant transformation of skin papillomas induced by chemical carcinogenesis, thus providing an in vivo evi-
dence for the oncogenic role of NANOG in squamous cell carcinomas6. Furthermore, NANOG has been found 
frequently aberrantly expressed in a variety of human cancers, including head and neck squamous cell carcino-
mas (HNSCC)6, 7. NANOG expression in cancer has been associated with chemoresistance8, 9, epithelial to mes-
enchymal transition (EMT)6 and poor clinical outcome7, 10–12.
Nevertheless, the role of NANOG in the early stages of HNSCC tumourigenesis and its possible implication in 
malignant transformation and acquisition of an invasive phenotype remains to be determined.
This prompted us to investigate NANOG protein expression in laryngeal tumourigenesis using a large series 
of 82 laryngeal precancerous lesions to establish correlations with clinicopathological parameters and the risk 
of progression to invasive carcinoma. This work unveils the clinical utility of NANOG expression as cancer risk 
marker in patients with laryngeal dysplasias, showing superior predictive power to histology. These results were 
further confirmed using an independent multicenter cohort of 86 patients with laryngeal premalignancies.
Results
NANOG protein expression in the early stages of laryngeal tumorigenesis. Immunohistochemical 
analysis of NANOG protein expression was performed on a set of 82 laryngeal dysplasias. Positive NANOG 
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expression was detected in the cytoplasm in 49 (60%) dysplasias (scored as 1 and 2), whereas expression was 
negligible in both stromal cells and normal adjacent epithelia (Fig. 1). Twenty-two (27%) lesions showed strong 
NANOG expression (score 2).
Cytoplasmic NANOG protein expression did not correlate with the histopathological classification: 9 (64%) of 
the 14 lesions with low-grade dysplasia, and 40 (59%) of the 68 lesions with high-grade dysplasia exhibited cyto-
plasmic NANOG protein expression (Chi-square P = 0.930). Strong NANOG expression was found in 4 (29%) 
low-grade dysplasias, and 18 (26%) high-grade dysplasias (Fisher’s exact P = 1.000). In addition, nuclear NANOG 
expression was detected in 7 dysplasias that also showed cytoplasmic expression: one case with weak and 6 cases 
with strong cytoplasmic expression (P = 0.001, Pearson ρ = 0.375).
Associations with laryngeal cancer risk. During the follow-up period, 24 (29%) of 82 patients developed 
an invasive carcinoma at the same site of the previous premalignant lesion. The mean time to cancer diagnosis 
in the cases that progressed was 28 months (range 6 to 66 months). No significant differences attributable to age 
Figure 1. Immunohistochemical analysis of NANOG expression in laryngeal dysplasias. Normal adjacent 
epithelia showed negative staining (A). Representative examples of low-grade dysplasias showing negative 
NANOG staining, score 0 (B) and cytoplasmic NANOG staining score 1 (C), a high-grade dysplasia with 
cytoplasmic NANOG staining score 2 (D), and a high-grade dysplasia with nuclear NANOG staining (E). 
Human seminoma was used as positive control, showing strong nuclear NANOG staining (F). Original 
magnification ×200 (E ×400).
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were observed (P = 0.703) between the group of patients who developed cancer (mean, 65 years) and those who 
did not (mean, 64 years). The mean tobacco consumption for patients who developed an invasive carcinoma was 
58.6 packs-year, compared to 52.7 packs-year for those who did not develop cancer (P = 0.316). Similarly, no 
significant differences in laryngeal cancer risk were observed between the subgroup of patients who continued 
smoking (14 patients) and those who ceased smoking (P = 0.757).
There was no statistically significant correlation in this cohort between the histopathological grade and the 
risk of progression to laryngeal cancer (P = 0.748; Table 1), although high-grade dysplasias showed a higher can-
cer risk (HR = 1.517, 95% CI 0.452 to 5.089; P = 0.499; Table 2).
Interestingly, we found that cytoplasmic NANOG protein scores significantly correlated with an increased 
laryngeal cancer risk (Table 1, and Fig. 2A, log-rank P = 0.007). Therefore, strong cytoplasmic NANOG expres-
sion (score 2) was used as a cut-off point in our subsequent analyses (Table 2, P = 0.003, and Fig. 2B, log-rank 
P = 0.002). Patients carrying strong cytoplasmic NANOG-expressing lesions (score 2) experienced a significantly 
higher progression to laryngeal cancer than those with absent to moderate (scores 0–1) expression (HR = 1.826; 
95%CI, 1.222–2.728; P = 0.003). At 5 years after the patients were diagnosed, 55% of the patients with strong 
cytoplasmic NANOG expression developed laryngeal cancer compared with 20% of the patients with negative to 
moderate NANOG expression (Fisher’s exact test, P = 0.005; Table 1). Nuclear NANOG expression also tended to 
associate with increased laryngeal cancer risk (Fisher’s exact test, P = 0.186; Table 1).
Univariate Cox analysis showed that strong cytoplasmic NANOG expression was the only significant pre-
dictor of laryngeal cancer risk (Table 2). The sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of cytoplasmic NANOG expression were 50%, 83%, 54%, and 80%, respectively.
Multicenter validation of NANOG as cancer risk marker. To further confirm these results, immuno-
histochemical analysis of NANOG expression was also carried out in an independent series of 86 laryngeal pre-
malignancies from two different collaborating institutions in Barcelona, Spain (Hospital de la Santa Creu i Sant 
Pau and Hospital Clínic). Cytoplasmic NANOG expression (scored as 1 and 2) was detected in 23 (27%) laryngeal 
dysplasias, and 7 (8%) lesions showed strong cytoplasmic NANOG expression. Nuclear NANOG expression was 
detected in nine of the cases with cytoplasmic expression; in 5 cases with weak and in 4 cases with strong cyto-
plasmic expression (P < 0.001, Pearson ρ = 0.6).
The proportion of cases with strong cytoplasmic expression was considerably lower than that observed in our 
exploratory series of laryngeal dysplasias from the Hospital Universitario Central de Asturias. However, note-
worthy the proportion of patients who developed an invasive carcinoma in the validation series was also notably 
low. Thus, during the follow-up period 10 (12%) patients developed an invasive carcinoma at the same biopsy site. 
More importantly, the results obtained in the validation cohort confirmed the relationship of NANOG expression 
Characteristic





Low-grade dysplasia 14(17) 3(21)
0.748†
High-grade dysplasia 68(83) 21(31)
Cytoplasmic NANOG protein scores
Negative (score 0) 33(40) 6(18)
0.009#Weak/Moderate (score 1) 27(33) 6(22)
Strong (score 2) 22(27) 12(55)
Cytoplasmic NANOG protein expression
Negative to Moderate 60(73) 12(20)
0.005†
Strong (score 2) 22(27) 12(55)




Table 1. Evolution of the premalignant lesions in relation to histopathological diagnosis and NANOG protein 
expression. #Chi-square and † Fisher’s exact tests.
Characteristic P Hazard Ratio 95% CI
-Age (above vs below the mean) 0.652 1.203 0.539 to 2.686
-Smoking (above vs below the mean) 0.41 1.4 0.629 to 3.119
-Histology (High-grade vs low-grade dysplasia) 0.499 1.517 0.452 to 5.089
-Cytoplasmic NANOG expression (Score 2 vs 0–1) 0.003 1.826 1.222 to 2.728
-Nuclear NANOG expression 0.063 2.773 0.945 to 8.134
Table 2. Univariate Cox Proportional Hazards Model to Estimate Laryngeal Cancer Risk in the exploratory 
cohort.
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with laryngeal cancer risk (Fig. 2C,D). Similarly, strong cytoplasmic NANOG expression showed the most robust 
association with laryngeal cancer risk, although the differences did not reach statistical significance, probably 
due to the small proportion of cases that progressed to cancer (log-rank P = 0.080; Fig. 2D), whereas histology 
was not a significant predictor of cancer development (log-rank P = 0.274). Nuclear NANOG expression was not 
associated with laryngeal cancer risk in this cohort (P = 0.59).
Also in this cohort, univariate Cox analysis showed that strong cytoplasmic NANOG expression was the 
better predictor of laryngeal cancer risk (Table 3). The sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) of cytoplasmic NANOG expression were 20%, 93%, 29%, and 90%, respectively.
Discussion
We recently reported that NANOG is frequently aberrantly expressed in squamous cell carcinomas, including 
HNSCC5. In addition, evidence was also provided to support that NANOG plays an active role in vivo, promoting 
malignant conversion of skin papillomas into carcinomas in transgenic mice6. To further and significantly extend 
these data, this study investigates for the first time NANOG expression in early stages of laryngeal tumourigenesis 
to uncover its role in malignant transformation and potential clinical application as cancer risk marker.
Using two large independent cohorts of patients with laryngeal precancerous lesions, we consistently demon-
strate that NANOG is frequently abnormally expressed in laryngeal dysplasias but not in normal adjacent epi-
thelia. More importantly, strong cytoplasmic NANOG protein expression (score 2) significantly correlated with 
higher cancer incidence in both patient cohorts. It is also worth noting that strong cytoplasmic NANOG expres-
sion showed the most robust association with laryngeal cancer risk and superior predictive power than the his-
tological classification, which remains the current gold standard in the clinical practice. Although the sensitivity 
Figure 2. Kaplan-Meier cancer-free survival curves in the exploratory series of 82 patients with laryngeal 
dysplasias categorized by NANOG protein scores (A) or NANOG protein expression dichotomized as strong 
(score 2) versus negative to moderate expression (scores 0–1) (B). Kaplan-Meier cancer-free survival curves 
in the validation series of 86 patients with laryngeal dysplasias categorized by NANOG protein scores (C) or 
NANOG protein expression dichotomized as strong (score 2) versus negative to moderate expression (scores 
0–1) (D). P values were estimated using the log-rank test.
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of cytoplasmic NANOG expression to detect patients who will develop laryngeal cancer was not high (50% and 
20% in the exploratory and the validation cohort, respectively), it consistently showed to be highly specific in the 
two independent cohorts analysed (83% and 93% in the exploratory and validation cohorts, respectively). Hence, 
this biomarker test is characterised by high negative predictive values and could therefore be helpful to identify 
patients at low probability of progression to laryngeal cancer. Consequently, clinical assessment of NANOG stain-
ing could be useful for ruling out the disease.
Regarding the differences in progression risk between the two patient cohorts, the higher laryngeal cancer risk 
observed in our patient series from Asturias may be attributed to demographic differences, since Asturias is the 
region with the highest laryngeal cancer incidence in Spain and also one of the highest in the world13. Consistent 
with this notion, the proportion of patients carrying lesions with strong NANOG expression was also higher 
in the exploratory cohort from Asturias, probably underlying that this population harbours more genetic and 
molecular alterations due to higher carcinogen exposure (as reflected by the higher tobacco consumption rates), 
which would ultimately provide an additional advantage for tumour formation.
Like other epithelial cancers, laryngeal carcinogenesis appears to evolve through a multistep process that 
involves biomolecular changes caused by carcinogen exposure, ensuing premalignant lesions and consequent 
invasive carcinoma14, 15. Although lesions with dysplastic features are thought to be at a higher cancer risk16, some 
cancers develop from lesions lacking dysplastic changes. Additional objective and reliable markers are there-
fore needed to identify more accurately high-risk lesions beyond current clinical and histopathological criteria17, 
which will undoubtedly help the clinicians to choose the most adequate therapeutic option. Since immunohis-
tochemical analysis of NANOG is relatively simple and easy to interpret, it seems reasonable to recommend 
this molecular test to be included as complementary marker for cancer risk assessment and decision-making. 
Nevertheless, routine implementation will require further confirmation of these results in large prospective 
studies.
Therefore, cytoplasmic NANOG expression emerges as a clinically and biologically relevant feature in early 
stages of laryngeal tumourigenesis that contributes to malignant transformation and laryngeal cancer develop-
ment. Aberrant NANOG expression appears to be a distinctive characteristic in human squamous cell carcino-
mas5, it has been associated to chemoresistance and poor disease outcome in various cancers7–12, 18, and according 
to the herein presented data, it also plays a prominent role in early stages of tumourigenesis and malignant 
transformation. NANOG immunostaining is usually detected in the nuclei of pluripotent cells, as shown in our 
seminoma control. Nuclear NANOG expression was also detected in laryngeal dysplasias; however, cytoplasmic 
NANOG expression was the most predominantly found and clinically relevant.
Our findings are in good agreement with previous reports that showed NANOG expression in the cytoplasm 
of tumour cells, associated with poor prognosis5, 11. Thus, cytoplasmic NANOG expression has been frequently 
detected in HNSCC tissue specimens5. Cytoplasmic NANOG expression has also been frequently detected in 
high-grade OSCC11. In addition, patients with strong NANOG expression exhibited significantly lower overall 
survival rates than those with weak or negative NANOG expression, suggesting that OSCCs with high cytoplas-
mic NANOG expression may possess aggressive characteristics, and ultimately poor prognosis11. In nasopharyn-
geal carcinomas, cytoplasmic NANOG was particularly evident at the invasive edge of tumours compared to low 
cytoplasmic NANOG expression in the non-cancerous epithelium, and showed clinical relevance associated to 
poor prognosis19. Similarly, cytoplasmic NANOG-positive stromal cells promoted human cervical cancer pro-
gression, with mesenchymal stem cells (MSCs) being one type of cytoplasmic NANOG-positive cells in cervical 
cancer stroma that participate in the progression of cervical cancer both in vitro and in vivo20.
The oncogenic role of NANOG involves transcriptional induction of an EMT program and stem cell features6, 18, 
leading to sustained unlimited growth, increased cell migration and acquisition of invasive phenotype. Hence, 
these data reflect that NANOG may represent a promising therapeutic target in the prevention and treatment of 
epithelial cancers.
Together our findings uncover a novel role for NANOG expression in laryngeal tumourigenesis, and its 
unprecedented clinical application as biomarker for cancer risk assessment in patients with precancerous lesions.
Methods
Patients and tissue specimens. Surgical tissue specimens from patients who were diagnosed of laryngeal 
dysplasia at the Hospital Universitario Central de Asturias between 1996 and 2010 were retrospectively collected, 
in accordance to approved institutional review board guidelines. All experimental protocols were approved by the 
Institutional Ethics Committee of the Hospital Universitario Central de Asturias and by the Regional CEIC from 
Principado de Asturias (approval number: 81/2013 for the project PI13/00259). Informed consent was obtained 




-Age (above vs below the mean) 0.826 1.149 0.332 to 3.973
-Smoking (above vs below the mean) 0.246 2.177 0.584 to 8.113
-Histology (High-grade vs low-grade dysplasia) 0.286 0.502 0.142 to 1.779
-Cytoplasmic NANOG expression (Score 2 vs 0-1) 0.1 1.906 0.876 to 4.148
-Nuclear NANOG expression 0.475 0.042 0.000 to 256.12
Table 3. Univariate Cox Proportional Hazards Model to Estimate Laryngeal Cancer Risk in the validation 
cohort.
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of laryngeal dysplasia; ii) with lesions of the vocal folds iii) no previous history of head and neck cancer; iv) com-
plete excisional biopsy of the lesion; v) a minimum follow-up of five years (or until progression to malignancy 
occurred); and vi) patients with a diagnosis of laryngeal dysplasia who developed cancer within the next six 
months were excluded from the study. Eighty-two consecutive patients who met these criteria were included in 
this study. All the patients were treated with macroscopically complete excisional biopsy of the lesion, either with 
CO2 laser or with cold instruments. Microscopically surgical margins were not assessed. No other treatments 
were administered. Patients were followed up every two months in the first six months after completing the treat-
ment, every three months until the second year, and every six months thereafter.
Representative tissue sections from the original biopsy material were obtained from archival, paraffin embed-
ded blocks and the histological diagnosis and epithelial dysplasia grade was confirmed in all the cases by an expe-
rienced pathologist (A.A.). The sections selected for study also contained normal epithelia as internal controls. 
After review, the premalignant lesions were classified into the categories of low-grade dysplasia (14 cases, 17%), 
and high-grade dysplasia (68 cases, 83%) following the WHO classification 4th Edition21.
All patients were men, with a mean age of 64 years (range 36-86 years). All but two patients were smokers, 44 
(54%) moderate (1-50 pack-year) and 36 (44%) heavy (>50 pack-year) smokers. The mean tobacco consumption 
was 54 pack-year (range 0-150). After the diagnosis, all the patients who were active smokers received smoking 
cessation advice; however, 14 of them continued smoking.
In addition, an independent cohort of 86 patients with a diagnosis of laryngeal dysplasia was used as a val-
idation series. This series included consecutive patients treated at two collaborating institutions in Barcelona 
(Hospital de la Santa Creu i Sant Pau and Hospital Clinic) between 1996 and 2010, who met the same inclusion 
criteria above-described for the exploratory series. Surgical tissue specimens were retrospectively collected, with 
the approval of their institutional review boards and in accordance to ethical and legal protection guidelines. The 
histological diagnosis and epithelial dysplasia grade was verified in all the cases by the same pathologist at our 
institution (A.A.), and after review, the premalignant lesions were classified into low-grade (22 cases, 26%), and 
high-grade dysplasia (64 cases, 74%) according to the WHO classification 4th Edition19.
All but seven patients were men, with a mean age of 62 years (range 30–87 years). All but nine patients were 
smokers, 47 (55%) moderate (1–50 pack-year) and 30 (35%) heavy (>50 pack-year) smokers. The mean tobacco 
consumption was 42 pack-year (range 0–120).
Immunohistochemistry. The formalin-fixed, paraffin-embedded tissues were cut into 3-µm sections and 
dried on Flex IHC microscope slides (Dako). The sections were deparaffinized with standard xylene and hydrated 
through graded alcohols into water. Antigen retrieval was performed using Envision Flex Target Retrieval solu-
tion, high pH (Dako). Staining was done at room temperature on an automatic staining workstation (Dako 
Autostainer Plus) with Nanog (D73G4) XP® Rabbit monoclonal antibody (Cell Signaling technology, Inc.) at 
1:200 dilution using the Dako EnVision Flex + Visualization System (Dako Autostainer). Counterstaining with 
haematoxylin was the final step.
A semiquantitative scoring system based on staining intensity was applied, as previously reported5. 
Immunostaining of the dysplastic areas was scored blinded to clinical data by two independent observers as 
negative (absence of staining, score 0), weak to moderate (some cytoplasmic staining in dysplastic areas, score 1), 
and strong protein expression (intense and homogeneous cytoplasmic staining in dysplastic areas, score 2), with a 
high level of inter-observer concordance (>95%). As in some cases nuclear staining was observed, the cases were 
also scored as positive/negative based on the presence of nuclear staining in dysplastic areas. Human seminoma 
was used as positive control, showing strong nuclear NANOG staining.
Statistical analysis. χ2 and Fisher’s exact tests were used for comparison between categorical variables. For 
time-to-event analysis, Kaplan-Meier curves were plotted. Differences between survival times were analysed by 
the log-rank method. Cox proportional hazards models were utilized for univariate analysis. The hazard ratios 
(HR) with 95% confidence interval (CI) and P values were reported. All tests were two-sided. p values of ≤0.05 
were considered statistically significant.
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